IP Library Granted Patent US 9,315,462
Granted Patent B2
US 9,315,462 · App. 14/817,329 · Granted Apr 19, 2016

Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors

Inventors: Xicheng Sun (Broomfield, CO); Jian Qiu (Longmont, CO); Adam Stout (Ann Arbor, MI)
Assignee: Nivalis Therapeutics, Inc.
C07D215/20C07D215/42C07D215/46C07D215/60C07D401/04C07D401/10C07D409/04C07D409/14C07D413/10C07D417/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,315,462
App. No.
14/817,329
Granted
Apr 19, 2016
Kind
B2
Abstract

The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

Claims (53)

1. The method of preparing a compound of Formula 1c, or a salt thereof,

the method comprising the step of coupling a compound of Formula 1a

with a compound Formula 1b

wherein:

m is selected from the group consisting of 0 and 1;

R 1 is independently selected from the group consisting of chloro, fluoro, bromo, cyano, and methoxy;

R 2b and R 2c are independently selected from the group consisting of hydrogen, chloro, fluoro, methyl, trifluoromethyl, cyano, methoxy, and N(CH 3 ) 2 ;

R A and R B are independently selected from the group consisting of H and Me;

R C and R D are independently or together a group that can by hydrolyzed to hydroxyl;

n is selected from the group consisting of 0 and 1; and

R 3 is independently selected from the group consisting of fluoro, chloro, bromo, methyl, trifluoromethyl, cyano, methoxy, and N(CH 3 ) 2 .

2. The method of claim 1 wherein m is 0.

3. The method of claim 1 wherein R C and R D are both OH or R C and R D together with the boron atom to which they are bound form a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group.

4. The method of claim 1 wherein R C and R D are both OH.

5. The method of claim 1 wherein R A is Me.

6. The method of claim 1 wherein R B is Me.

7. The method of claim 1 wherein R A and R B are both H.

8. The method of claim 1 wherein the method comprises a demethylation step using BBr 3 , AlCl 3 , or Na2S.

9. The method of claim 6 wherein the method comprises an ester hydrolysis step using LiOH or NaOH.

10. The method of claim 1 wherein the coupling step uses PdCl 2 (dppf) or Pd(PPh 3 ) 4 .

11. The method of claim 1 wherein the compound 1c is selected from the group consisting of

4-(6-hydroxy-3-methylquinolin-2-yl)benzoic acid;

4-(6-hydroxyquinolin-2-yl)benzoic acid;

3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid;

2-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid;

2-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid;

3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid;

4-(6-hydroxyquinolin-2-yl)-3-methoxybenzoic acid;

4-(3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(4-chloro-3-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(3-chloro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(4-chloro-6-hydroxyquinolin-2-yl)benzoic acid;

3-(dimethylamino)-4-(6-hydroxyquinolin-2-yl)benzoic acid;

4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid;

4-(3-chloro-6-hydroxyquinolin-2-yl)-3-fluorobenzoic acid;

4-(6-hydroxyquinolin-2-yl)-3-(trifluoromethyl)benzoic acid;

4-(6-hydroxy-3-(trifluoromethyl)quinolin-2-yl)benzoic acid;

3-chloro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

3-fluoro-4-(4-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(5-chloro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(5-bromo-6-hydroxyquinolin-2-yl)benzoic acid;

3-bromo-4-(6-hydroxyquinolin-2-yl)benzoic acid;

4-(4-(dimethylamino)-6-hydroxyquinolin-2-yl)benzoic acid;

4-(4-fluoro-6-hydroxyquinolin-2-yl)-3-methoxybenzoic acid;

3-cyano-4-(6-hydroxyquinolin-2-yl)benzoic acid;

4-(3-cyano-6-hydroxyquinolin-2-yl)benzoic acid;

4-(5-fluoro-6-hydroxyquinolin-2-yl)benzoic acid;

4-(8-fluoro-6-hydroxyquinolin-2-yl)benzoic acid; and

3-fluoro-4-(5-fluoro-6-hydroxyquinolin-2-yl)benzoic acid.

12. The method of claim 1 wherein the compound 1c is 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid.

13. The method of claim 1 wherein the compound 1c is 3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid.

14. The method of claim 1 wherein the compound 1c is 4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2019
From: LAUREL VENTURE CAPITAL LTD.
To: LAUREL THERAPEUTICS LTD.
Reel/Frame 048787/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 13, 2018
From: ALPINE IMMUNE SCIENCES, INC.
To: LAUREL VENTURE CAPITAL LTD.
Reel/Frame 046341/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2015
From: SUN, XICHENG; QIU, JIAN; STOUT, ADAM
To: N30 PHARMACEUTICALS, LLC
Reel/Frame 036283/0265 →
CHANGE OF NAME Recorded Aug 5, 2015
From: N30 PHARMACEUTICALS, LLC
To: N30 PHARMACEUTICALS, INC.
Reel/Frame 036283/0268 →
CHANGE OF NAME Recorded Aug 5, 2015
From: N30 PHARMACEUTICALS, INC.
To: NIVALIS THERAPEUTICS, INC.
Reel/Frame 036283/0280 →
Continuity (5)
Continuation 14540216 · Nov 13, 2014
Continuation 13824430
Provisional Application 61391225 · Oct 8, 2010
Provisional Application 61423805 · Dec 16, 2010
Related Publication 20150336897A1 · Nov 26, 2015